Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-centre, Parallel-group, Open Label, Oncaspar® Controlled Dose Ranging Trial of Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia

NCT01251809 is registered in ClinicalTrials.gov with medac GmbH as lead sponsor.

NCT NCT01251809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01251809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-centre, Parallel-group, Open Label, Oncaspar® Controlled Dose Ranging Trial of Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia
Lead sponsor
medac GmbH
Phase
Phase 1/2
Overall status
Terminated
Start date
January 31, 2011
Completion date
May 31, 2013
Enrollment
56 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukaemia